thalidomide has been researched along with Death, Sudden in 1 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Death, Sudden: The abrupt cessation of all vital bodily functions, manifested by the permanent loss of total cerebral, respiratory, and cardiovascular functions.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Thalidomide was therefore suggested as atherapeutic intervention for the treatment of ALS." | 6.73 | Thalidomide causes sinus bradycardia in ALS. ( Borisow, N; Dullinger, JS; Linke, P; Maier, A; Meyer, T; Münch, C; Ohlraun, S; Splettstösser, G, 2008) |
| "Thalidomide was therefore suggested as atherapeutic intervention for the treatment of ALS." | 2.73 | Thalidomide causes sinus bradycardia in ALS. ( Borisow, N; Dullinger, JS; Linke, P; Maier, A; Meyer, T; Münch, C; Ohlraun, S; Splettstösser, G, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Meyer, T | 1 |
| Maier, A | 1 |
| Borisow, N | 1 |
| Dullinger, JS | 1 |
| Splettstösser, G | 1 |
| Ohlraun, S | 1 |
| Münch, C | 1 |
| Linke, P | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Randomized, Open, Parallel Group Study for the Evaluation of an Oral Dose of 100 mg Thalidomide and Subsequent Dose Escalation of 400 mg Thalidomide in Combination With Riluzole in Patients With Amyotrophic Lateral Sclerosis (ALS)[NCT00231140] | Phase 2 | 40 participants | Interventional | 2005-12-31 | Terminated | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for thalidomide and Death, Sudden
| Article | Year |
|---|---|
Thalidomide causes sinus bradycardia in ALS.
Topics: Adult; Aged; Amyotrophic Lateral Sclerosis; Anti-Inflammatory Agents; Arrhythmia, Sinus; Bradycardia | 2008 |